174 related articles for article (PubMed ID: 11843241)
1. Adjuvant interferon-alpha for melanoma revisited: news from old and new studies.
Punt CJ; Eggermont AM
Ann Oncol; 2001 Dec; 12(12):1663-6. PubMed ID: 11843241
[TBL] [Abstract][Full Text] [Related]
2. The role interferon-alpha in malignant melanoma remains to be defined.
Eggermont AM
Eur J Cancer; 2001 Nov; 37(17):2147-53. PubMed ID: 11677100
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy in melanoma.
Mohr P; Weichenthal M; Hauschild A
Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
[TBL] [Abstract][Full Text] [Related]
4. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials.
Lens MB; Dawes M
J Clin Oncol; 2002 Apr; 20(7):1818-25. PubMed ID: 11919239
[TBL] [Abstract][Full Text] [Related]
5. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
Mocellin S; Pasquali S; Rossi CR; Nitti D
J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
[TBL] [Abstract][Full Text] [Related]
6. Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival?
Eggermont AM; Punt CJ
Am J Clin Dermatol; 2003; 4(8):531-6. PubMed ID: 12862495
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
9. Potential of interferon-alpha in solid tumours: part 1.
Decatris M; Santhanam S; O'Byrne K
BioDrugs; 2002; 16(4):261-81. PubMed ID: 12196039
[TBL] [Abstract][Full Text] [Related]
10. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.
Suciu S; Eggermont AMM; Lorigan P; Kirkwood JM; Markovic SN; Garbe C; Cameron D; Kotapati S; Chen TT; Wheatley K; Ives N; de Schaetzen G; Efendi A; Buyse M
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922786
[TBL] [Abstract][Full Text] [Related]
11. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials.
Wheatley K; Ives N; Hancock B; Gore M; Eggermont A; Suciu S
Cancer Treat Rev; 2003 Aug; 29(4):241-52. PubMed ID: 12927565
[TBL] [Abstract][Full Text] [Related]
12. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
Verma S; Quirt I; McCready D; Bak K; Charette M; Iscoe N
Cancer; 2006 Apr; 106(7):1431-42. PubMed ID: 16511841
[TBL] [Abstract][Full Text] [Related]
14. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
Schuchter LM
J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
[No Abstract] [Full Text] [Related]
18. Adjuvant interferon therapy for melanoma.
Hancock B; Wheatley K; Ives N; Gore M
J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
[No Abstract] [Full Text] [Related]
19. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review.
Ascierto PA; Gogas HJ; Grob JJ; Algarra SM; Mohr P; Hansson J; Hauschild A
Crit Rev Oncol Hematol; 2013 Feb; 85(2):149-61. PubMed ID: 22874771
[TBL] [Abstract][Full Text] [Related]
20. Melanoma and IFN alpha: potential adjuvant therapy.
Bottoni U; Clerico R; Paolino G; Corsetti P; Ambrifi M; Brachini A; Richetta A; Nisticò S; Pranteda G; Calvieri S
J Biol Regul Homeost Agents; 2014; 28(2):271-9. PubMed ID: 25001659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]